XML 79 R44.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Revenue - Composition of Total Revenue by Product and by U.S versus Rest of World (Detail) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Disaggregation Of Revenue [Line Items]        
Total revenue $ 195.1 $ 216.8 $ 381.4 $ 419.1
U.S. [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 182.3 205.8 357.0 397.5
RoW [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 12.9 11.0 24.5 21.6
Molecular Diagnostic - Hereditary Cancer Testing [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 117.7 126.7 222.2 243.1
Molecular Diagnostic - Hereditary Cancer Testing [Member] | U.S. [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 112.9 123.4 213.5 237.0
Molecular Diagnostic - Hereditary Cancer Testing [Member] | RoW [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 4.8 3.3 8.7 6.1
Molecular Diagnostic - GeneSight [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 22.5 24.0 45.2 53.2
Molecular Diagnostic - GeneSight [Member] | U.S. [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 22.5 24.0 45.2 53.2
Molecular Diagnostic - Prenatal [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 16.4 31.2 39.9 49.3
Molecular Diagnostic - Prenatal [Member] | U.S. [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 16.3 31.2 39.8 49.3
Molecular Diagnostic - Prenatal [Member] | RoW [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 0.1   0.1  
Molecular Diagnostic - Vectra [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 10.3 11.8 21.4 24.8
Molecular Diagnostic - Vectra [Member] | U.S. [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 10.3 11.8 21.4 24.8
Molecular Diagnostic - Prolaris [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 6.8 6.1 13.3 12.3
Molecular Diagnostic - Prolaris [Member] | U.S. [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 6.7 6.1 13.2 12.3
Molecular Diagnostic - Prolaris [Member] | RoW [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 0.1   0.1  
Molecular Diagnostic - EndoPredict [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 2.6 2.2 4.8 4.6
Molecular Diagnostic - EndoPredict [Member] | U.S. [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 0.5 0.4 0.9 0.7
Molecular Diagnostic - EndoPredict [Member] | RoW [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 2.1 1.8 3.9 3.9
Molecular Diagnostic - Other [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 4.8 1.0 6.3 4.7
Molecular Diagnostic - Other [Member] | U.S. [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 4.8 0.7 6.2 4.4
Molecular Diagnostic - Other [Member] | RoW [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue   0.3 0.1 0.3
Molecular Diagnostic Testing [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 181.1 203.0 353.1 392.0
Molecular Diagnostic Testing [Member] | U.S. [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 174.0 197.6 340.2 381.7
Molecular Diagnostic Testing [Member] | RoW [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 7.1 5.4 12.9 10.3
Pharmaceutical and Clinical Services [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 14.0 13.8 28.3 27.1
Pharmaceutical and Clinical Services [Member] | U.S. [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 8.3 8.2 16.8 15.8
Pharmaceutical and Clinical Services [Member] | RoW [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue $ 5.8 $ 5.6 $ 11.6 $ 11.3